CSPC Pharmaceutical's EBT Buys 8.5 Million Shares

CSPC Pharmaceutical Group's (HKG:1093) employee benefit trust (EBT) purchased close to 8.5 million CSPC shares via two transactions on the secondary market this week, according to separate filings wit

MT NewswiresApr 24 09:28 ET

CSPC Group (01093.HK): The trustee purchased 5.54 million shares under the share incentive plan

Gelonghui, April 24, 丨 Shiyao Group (01093.HK) announced that on April 24, 2024, the plan trustee (“trustee”) purchased a total of 5.54 million shares of the company on the market in accordance with the terms and conditions of the plan and held such shares in trust for the benefit of the selected participants.

Gelonghui FinanceApr 24 05:36 ET

Shiyao Group (01093): The trustee purchased a total of 2,934 million shares under the share award scheme

Shiyao Group (01093) issued an announcement. On April 23, 2024, the plan trustee, in accordance with the terms of the plan and...

Zhitong FinanceApr 23 05:54 ET

Shiyao Group: The net profit of CSPC Innovation in the first quarter was about 79.0613 million yuan, a year-on-year decrease of 38.86%

Shiyao Group (01093) announced the results of Shiyao Innovation (300765.SZ) for the first quarter of 2024, with operating income of about 524 million yuan, a year-on-year decrease of 27.08%; net profit attributable to shareholders of listed companies was about 79.0613 million yuan, a year-on-year decrease of 38.86%; and basic earnings per share were 0.0676 yuan.

新浪港股Apr 22 21:02 ET

Shiyao Group (01093): The net profit of Shiyao Innovation (300765.SZ) in the first quarter was about 79.0613 million yuan, a year-on-year decrease of 38.86%

According to Zhitong Finance App News, Shiyao Group (01093) announced the results of Shiyao Innovation (300765.SZ) for the first quarter of 2024, with operating revenue of about 524 million yuan, a year-on-year decrease of 27.08%; net profit attributable to shareholders of listed companies was about 79.0613 million yuan, a year-on-year decrease of 38.86%; and basic earnings per share were 0.0676 yuan. According to the announcement, the main reason for the decline in revenue was the decline in main business revenue during the reporting period due to a decrease in the price of caffeine products compared to the same period last year. At the same time, Jushi Biotech authorized the overseas development and commercialization of Nectin4 ADC products during the same period last year

Zhitong FinanceApr 22 09:35 ET

石藥集團：內幕消息 - 石藥創新製藥股份有限公司截至2024年3月31日止3個月之主要財務資料

Futu NewsApr 22 09:32 ET · Announcements